Drugs / Monomethyl Auristatin E
Monomethyl Auristatin E
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 0 | NCT07198659 Background | Jul 2025 → Jul 2027 expected | pancreas disorder | The First Affiliated Hospital of Air Force Medicial University | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Monomethyl Auristatin E | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07198659 ↗ |
| Known as | MMAE | “Neutrophils will be isolated using a blood cell separator and cultured in a GMP-compliant laboratory to prepare neutrophil biological agents, which will then be loaded with the...” NCT07198659 ↗ |
| Known as | SGD-1010 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594216 ↗ |
| Modality | Peptide | “the anti-tumor peptide, Monomethyl Auristatin E (MMAE)” NCT07198659 ↗ |